Bli medlem
Bli medlem

Du är här



Small but heading for the big time

Nanobiotix: 2014 Annual Results

Paris, France, 14 April, 2015
- NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205)
, a late clinical-stage nanomedicine company pioneering novel approaches for
the local treatment of cancer, announces today its audited consolidated
results for the fiscal year ended December 31, 2014:

* Revenue increased mainly as a result of a milestone payment received from
PharmaEngine to develop the Soft Tissue Sarcoma indication in the
Asia-Pacific region;
* Expenses were impacted by Nanobiotix's R&D expansion, which has taken lead
product NBTXR3 into pivotal phase II/III trials in Soft Tissue Sarcoma and
pilot studies in Head and Neck cancer.

Philippe MAUBERNA, Chief Financial Officer of Nanobiotix commented: "This has
been an important year for Nanobiotix. The two fundraisings completed
in 2014 have put Nanobiotix in a strong cash position. The additional €38.5m
raised in 2014 should enable us to execute our global strategic development
and in particular the preparation for an anticipated CE mark of NBTXR3 by the
end of 2016

· Income statement

| 2014 2013 |
| (1) |
| Total revenue 2,770,795 1,595,466 |
|€ |
| Sales 967,500 184,938 |
| |
| |
| |
| |
| |
|Other revenue 1,803,295 1,410,528 |
| |
|Subsidies 314,764 80,973 |
|Research Tax Credit 1,483,122 1,324,517 |
|Other 5,408 5,038 |
| Cost of sales - - |
| R&D costs (8,075,723) (6,025,677) |
| General costs (4,062,591) (3,151,249) |
| Costs associated with payments in shares (252,257) (597,958) |
| Core operating loss (9,619,777) (8,179,418) |
| Financial gain / (charges) (*) 142,522 34,497 |
| Core pre-tax loss (9,477,255) (8,144,920) |
| Tax (79,271) - |
| Net Profit&Loss (9,556,525) (8,144,920) |

* cost of net financial debt and other financial expenses
(1) non audited accounts

· Financial Review

NANOBIOTIX's sole source of revenue corresponds to the payments received from
its Taiwanese partner, PharmaEngine, within the framework of the licensing
contract. This contract is for the development and marketing of NBTXR3 in the
Asia-Pacific region. In total, the upfront payment received in August 2012
was €810,640. The revenue has been deferred using the straight-line method
between the date the contract was signed and the scheduled marketing launch
in that region.

For the 12 months ended 31 December 2014, the pro-rata share of revenue was
€183,892. Revenue for the year also includes a milestone payment of $1.0m
(€783,607) received from PharmaEngine in October 2014 reflecting the fact
that PharmaEngine will join Nanobiotix's pivotal trial for NBTXR3 in Soft
Tissue Sarcoma to accelerate the product's development in the Asia-Pacific
region. In accordance with the contract between Nanobiotix and PharmaEngine,
Nanobiotix is eligible to receive development and commercialization milestone
payments up to $56.0m plus tiered, up to double-digit royalties on all net
product sales in the Asia-Pacific region.

Total revenue includes subsidies and research tax credit which have risen
sharply, as levels of R&D have increased during the 2014.

R&D costs increased by €2m in line with the accelerated pipeline development,
particularly around the progress of the lead product, NBTXR3. NBTXR3, which
is currently being tested in patients with advanced Soft Tissue Sarcoma
(STS), entered product registration phase (pivotal) in October 2014.
Depending on the results, this could allow the Company to obtain a CE mark in
late 2016. NBTXR3 is also being developed in Head and Neck cancer. The
Company aims to expand its clinical development program, in the second
half-year of 2015, with new high potential indications in the US and Europe:
liver cancers (primary and metastatic) and prostate cancer. The NanoXray
platform is also being developed in two other administration pathways, a gel
form that is applied in the tumor bed during surgery (NBTX-TOPO), and as an
intravenous injection (NBTX-IV). R&D costs reflect also the strengthening of
the teams to support pipeline development.

General and administration costs recorded by the Company increased by €0.9m in
line with expectations. These costs are mostly due to the new US strategic
development and preparation of all steps to future commercialization.

The core operating loss was €9,619,777 (FY13: loss €8,179,418).

The financial gain was €142,522 (FY13: financial gain of €34,497) which
corresponds to interest income on the short term bank deposits following both
capital increases of 2014.

The tax recorded in 2014 relates to the tax withholding from the PharmaEngine
milestone payment of US$1m related to PharmaEngine joining Nanobiotix's
pivotal trial in Soft Tissue Sarcoma.

The net loss was €9,556,525 (FY13: loss 8,144,920).

· Post year end events

In February 2015, the Company announced that Professor Robert Langer,
Institute Professor at the Massachusetts Institute of Technology (MIT),
became a Scientific Advisor to Nanobiotix. Professor Langer presides over the
largest academic biomedical engineering laboratory in the world. Beyond his
extensive involvement and leadership in MIT's scientific community, Professor
Langer's research has spawned a vast array of innovative and disruptive
technologies. He holds over 1,000 patents in diverse areas of biomedical
technology and has been involved in the launch or acceleration of numerous
biotech companies.

Moreover, in March 2015, Nanobiotix appointed its Manufacturing Partner,
CordenPharma. The new manufacturing line, located in France, will increase
the amount of NBTXR3 product available. With a CE mark anticipated in 2016,
the Company is preparing to scale-up production further to meet the needs of
future commercialization. Furthermore, Nanobiotix is anticipating an increase
in demand for product for clinical trials in the coming years in Europe and
in the United States. The opening of a new manufacturing line and the scaling
up of production are important steps in NBTXR3's route to commercialization.


Next financial press release: revenue for Q1 2015 on May 15, 2015.


Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage
nanomedicine company pioneering novel approaches for the local treatment of
cancer. The Company's first-in-class, proprietary technology, NanoXray,
enhances radiotherapy energy with a view to provide a new, more efficient
treatment for cancer patients. NanoXray products are compatible with current
radiotherapy treatments and are meant to treat potentially a wide variety of
cancers including Soft Tissue Sarcoma, Head and Neck Cancer, Liver Cancers,
Prostate Cancer, Breast Cancer, Glioblastoma, etc., via multiple routes of

Nanobiotix's lead product NBTXR3, based on NanoXray, is currently under
clinical development for Soft Tissue Sarcoma and locally advanced Head and
Neck Cancer. The Company has partnered with PharmaEngine for clinical
development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN:
FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company, based
in Paris, France, opened an affiliate office in the Boston area of the United
States in September 2014.


| Nanobiotix |
| Sarah Gaubert |
|Head of Communication and Public Affairs |
|+33 (0)1 40 26 07 55 |
| |
| Media relations |
| France - NewCap Outside France - Instinctif Partners |
|Annie-Florence Loyer Melanie Toyne Sewell / Ruth Ashton / Emma Barlow |
|+33 (0)6 88 20 35 59 +44 (0) 207 457 2020 |
| |

This press release contains certain forward-looking statements concerning
Nanobiotix and its business. Such forward-looking statements are based on
assumptions that Nanobiotix considers to be reasonable. However, there can be
no assurance that the estimates contained in such forward-looking statements
will be verified, which estimates are subject to numerous risks including the
risks set forth in the
reference document of Nanobiotix registered by the French Financial Markets
Authority (Autorité des marchés financiers) on November 25, 2014 under number
(a copy of which is available on and to the development of
economic conditions, financial markets and the markets in which Nanobiotix
operates. The forward-looking statements contained in this press release are
also subject to risks not yet known to Nanobiotix or not currently considered
material by Nanobiotix. The occurrence of all or part of such risks could
cause actual results, financial conditions, performance or achievements of
Nanobiotix to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute ...

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.